AI-Assisted Technology Platform to Be Used in Hunt for Most Effective COVID-19 Treatments
By HospiMedica International staff writers
Posted on 16 Jul 2020
New tools for automated network meta-analysis are now being used in the hunt for the most effective treatments for COVID-19.Posted on 16 Jul 2020
Doctor Evidence (DRE Santa Monica, CA, USA), a Software-as-a-Service (SaaS) company in the AI-enabled health technology marketplace, is offering its DOC Analytics platform for real time aggregation of all the clinical trial data that is continuously emerging.
Currently, about 1,798 COVID-19 treatment trials are underway across the world and preliminary results and data from high-profile trials are now available, including for Remdesivir, Dexamethasone, and Hydroxychloroquine. DRE is using its first-in-industry DOC Analytics platform to generate real-time network meta-analysis for researchers to produce quantitative analysis for any therapeutic question in the global landscape. This approach will inform decision-makers with regard to real-time updates from clinical trials for quantitative comparison, analysis, and reporting on relevant outcomes.
This novel quantitative analytic approach leverages DRE’s open DOC Search platform for COVID-19, which makes available annotated set of literature from CORD19, the open research dataset made available by the Allen Institute in response to the White House Task Force call to action in late March. DOC Search provides the foundation of medical conceptual organization to identify which key concepts are being reported across literature and trials.
“We are breaking new ground in AI-assisted technology at a critical time for healthcare,” said Bob Battista, MBA, FRCPH, FRCP Edin., Co-founder and Chief Executive Officer of DRE. “Our industry-first automated network meta-analysis technology and AI-enabled search engine are being utilized for rapid assessment of drug candidates for COVID-19. DOC Search and Analytics are being used as a foundational tool by top 10 industry ranked global pharmaceutical/life science companies that are DRE clients.”
Related Links:
Doctor Evidence